These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19385162)

  • 1. Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors.
    Chung CH; O'Neil BH
    Oncology (Williston Park); 2009 Feb; 23(2 Suppl 1):14-7. PubMed ID: 19385162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infusion reactions associated with monoclonal antibodies in patients with solid tumors. Introduction.
    Cmelak AJ; Goldberg RM
    Oncology (Williston Park); 2009 Feb; 23(2 Suppl 1):5-6. PubMed ID: 19385160
    [No Abstract]   [Full Text] [Related]  

  • 3. Infusion reactions triggered by monoclonal antibodies treating solid tumors.
    Carney PH; Ollom CL
    J Infus Nurs; 2008; 31(2):74-83. PubMed ID: 18344767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute infusion reactions induced by monoclonal antibody therapy.
    Maggi E; Vultaggio A; Matucci A
    Expert Rev Clin Immunol; 2011 Jan; 7(1):55-63. PubMed ID: 21162650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of infusion reactions in clinical trials and beyond: the US and EU perspectives.
    Cmelak AJ; Lordick F; Borner M; Goldberg RM; Saif MW
    Oncology (Williston Park); 2009 Feb; 23(2 Suppl 1):18-25. PubMed ID: 19385163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaphylaxis: implications of monoclonal antibody use in oncology.
    Gleich GJ; Leiferman KM
    Oncology (Williston Park); 2009 Feb; 23(2 Suppl 1):7-13. PubMed ID: 19385161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing drug infusion reactions: focus on cetuximab monoclonal antibody therapy.
    Wilkes G
    Clin J Oncol Nurs; 2008 Jun; 12(3):530-2. PubMed ID: 18515254
    [No Abstract]   [Full Text] [Related]  

  • 8. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies.
    Hong DI; Bankova L; Cahill KN; Kyin T; Castells MC
    Expert Rev Clin Immunol; 2012 Jan; 8(1):43-52; quiz 53-4. PubMed ID: 22149339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management and preparedness for infusion and hypersensitivity reactions.
    Lenz HJ
    Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
    Chung CH
    Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Infusion reactions].
    Sato K; Kohgo Y
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1671-4. PubMed ID: 18931569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab-associated infusion reactions: pathology and management.
    Patel DD; Goldberg RM
    Oncology (Williston Park); 2006 Oct; 20(11):1373-82; discussion 1382, 1392-4, 1397. PubMed ID: 17112000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor-monoclonal antibodies and desensitization.
    Labella M; Castells M
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):623-629. PubMed ID: 33781937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.
    Hopps S; Medina P; Pant S; Webb R; Moorman M; Borders E
    J Oncol Pharm Pract; 2013 Sep; 19(3):222-7. PubMed ID: 23135806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.
    Augustsson J; Eksborg S; Ernestam S; Gullström E; van Vollenhoven R
    Ann Rheum Dis; 2007 Nov; 66(11):1462-6. PubMed ID: 17502359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management.
    Kang SP; Saif MW
    J Support Oncol; 2007 Oct; 5(9):451-7. PubMed ID: 18019853
    [No Abstract]   [Full Text] [Related]  

  • 17. [Infusion reaction and anaphylaxis].
    Yoshida K; Shiono M; Ishioka C
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1753-7. PubMed ID: 22083179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab: adverse event profile and recommendations for toxicity management.
    Thomas M
    Clin J Oncol Nurs; 2005 Jun; 9(3):332-8. PubMed ID: 15973844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaphylaxis to thymoglobulin: a case report and literature review.
    Kandil E; Alabbas H; Distant D
    J La State Med Soc; 2009; 161(5):279-81. PubMed ID: 19927941
    [No Abstract]   [Full Text] [Related]  

  • 20. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
    Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
    Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.